Longeveron to Present 5-Year Survival Data for Hypoplastic Left Heart Syndrome Therapy

MT NewswiresOct 9 10:07 ET

Express News | Longeveron Lomecel-B 5-Year Long-Term Transplant-Free Survival Data In HLHS Selected For Oral Presentation At Congenital Heart Surgeons' Society 51st Annual Meeting

BenzingaOct 9 09:06 ET

Longeveron to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Yahoo FinanceOct 7 09:05 ET

Longeveron to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GlobeNewswireOct 2 09:05 ET

Buy Rating Affirmed for Longeveron on Favorable Lomecel-B Regulatory Outlook and Trial Progress

TipRanksSep 4 06:27 ET · Ratings

Express News | Longeveron Inc - Alignment With FDA on Elpis II Primary and Secondary Endpoints

ReutersSep 3 09:00 ET